74
Participants
Start Date
August 19, 2020
Primary Completion Date
July 31, 2025
Study Completion Date
July 31, 2025
RO7248824
In the MAD part, RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration. In the LTE part, RO7248824 will be administered as IT injection of varying dose levels over a period of 144 weeks, with a minimum of approximately 16 weeks between each dose administration. In the OOE part, participants will receive RO7248824 as an IT injection with the same dosing regime as the LTE part over a period of up to 48 weeks.
Columbia University Medical Center, New York
Carolina Institute for Development DisabilitiesUniversity of North Carolina/School of Medicine, Carrboro
Hospital Universitario Virgen del Rocío, Seville
Mayo Clinic - Rochester, Rochester
Rush Medical Center, Chicago
Baylor College of Med, Houston
UCLA Neuropsychiatric Institute, Los Angeles
Rady Children's Hospital - San Diego, San Diego
Ospedale Pediatrico Bambino Gesù, Rome
Erasmus MC / location Sophia Kinderziekenhuis, Rotterdam
Hospital Sant Joan De Deu, Esplugues de Llobregas
Corporacio Sanitaria Parc Tauli, Sabadell
Hoffmann-La Roche
INDUSTRY